Ronald Blue Trust, Inc. Celldex Therapeutics, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 59 shares of CLDX stock, worth $1,545. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59
Previous 3
1866.67%
Holding current value
$1,545
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$242 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$123 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$101 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$90.6 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$87.3 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.23B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...